A commonly used arthritis medication failed to improve symptoms in people with a specific form of knee osteoarthritis, according to an article published June 2 in JAMA Internal Medicine.
In a randomized clinical trial, researchers tested low-dose methotrexate, a drug often prescribed for rheumatoid arthritis, in 215 patients with inflammatory knee osteoarthritis and effusion-synovitis. The trial was conducted across 11 sites in China between 2019 and 2023, with more than 80% of enrolled participants completing the study.
Over the 52-week trial, the study showed there was no statistically significant difference in pain or joint swelling between the methotrexate and a placebo.
Specifically, researchers found no difference in knee pain scores and in the area of effusion-synovitis, suggesting the drug did not provide meaningful symptom relief or disease modification.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
